Sanofi

News

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.

News

Sanofi to buy UK vaccines developer Vicebio for $1.6bn

Sanofi has agreed to buy UK start-up Vicebio, set up to produce improved, more potent shots that are simpler to manufacture, for $1.15bn upfront.

News

FDA fast-tracks Sanofi's gene therapy for eye disease GA

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy, a major cause of blindness.

News

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another.

News

Dupixent is first FDA-approved drug for rare skin disease

The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.

News

Beyfortus now has a direct rival after FDA OK for Enflonsia

MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Sanofi to buy UK vaccines developer Vicebio for $1.6bn

FDA fast-tracks Sanofi's gene therapy for eye disease GA

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Dupixent is first FDA-approved drug for rare skin disease

Beyfortus now has a direct rival after FDA OK for Enflonsia

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Sanofi

Editor's Picks